Trefoil Therapeutics Inc.'s $28 million from an oversubscribed series A financing will let the company finish a phase IIa proof-of-concept study as researchers edge toward attacking corneal endothelial dystrophy, including Fuchs dystrophy, a disease that leads to the deterioration of the endothelial layer on the back surface of the cornea.

DUBLIN – Early stage vaccine developer Osivax SAS raised €8 million (U$9 million) in series A funding to continue development of a clinical-stage universal influenza vaccine, based on what it believes is a highly immunogenic method of presenting the viral nucleoprotein to the immune system.

Xealth Inc., of Seattle, closed a series A financing with an additional $3 million from new investors Atrium Health, Cleveland clinic and Memorialcare Innovation Fund. The proceeds, which now total $14 million, will go toward further developing and deploying the company's digital prescribing and analytics platform. The company focuses on helping health systems organize and utilize digital health tools to optimize workflow, patient engagement and financial results.